Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease

G De Rubis, KR Paudel, L Corrie, S Mehndiratta… - Naunyn-Schmiedeberg's …, 2024 - Springer
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are among the
leading causes of mortality worldwide. Cigarette smoking is among the main aetiologic …

The association between a decrease in on-treatment neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical …

YW Chen, MD Tucker, LC Brown, HA Yasin, KK Ancell… - Cancers, 2022 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICIs) have significantly changed the
treatment paradigm in metastatic renal cell carcinoma (mRCC) and brought an …

Sex differences in presentation, treatment, and survival in patients receiving palliative (chemo) radiotherapy for non-small cell lung cancer

C Nieder, SG Aanes, A Dalhaug… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: The aim of this study was to analyze sex differences in a real-world cohort
of patients who received palliative thoracic radiotherapy or chemoradiotherapy for non-small …

Fecal microbiome extract downregulates the expression of key proteins at the interface between airway remodelling and lung cancer pathogenesis in vitro

G De Rubis, KR Paudel, S Vishwas, S Kokkinis… - … -Research and Practice, 2024 - Elsevier
Lung cancer (LC) is the leading cause of cancer-related mortality, and it is caused by many
factors including cigarette smoking. Despite numerous treatment strategies for LC, its five …

Development of novel small antitumor compounds inhibiting PD-1/PD-L1 binding

Y Akiyama, T Ashizawa, A Iizuka, T Ando… - Anticancer …, 2022 - ar.iiarjournals.org
Abstract Background/Aim: Anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) antibody is
a successful treatment for patients with solid cancers; however, there are several …

In Vivo Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models

T Ashizawa, A Iizuka, A Kanematsu, T Ando, C Maeda… - in vivo, 2025 - iv.iiarjournals.org
Background/Aim: Immune checkpoint blockade has achieved great success as a targeted
immunotherapy for solid cancers. However, small molecules that inhibit programmed death …

Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)

T Tamura, T Numata, H Yanai, R Nakamura… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Atezolizumab, an anti-programed death-ligand 1 monoclonal antibody,
targets programed death-ligand 1 expressed on cancer cells and antigen-presenting cells …

Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER

K Endo, H Tanaka, H Matsuo, T Onoda… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: There have been advances in the development of immune checkpoint
inhibitors for monotherapy and combination therapy with other anticancer agents in recent …

Say 'No'to Cancer and 'Yes' to Cranberry: The Role of Cranberry Extract in Inhibition of Growth of Lung Adenocarcinoma Cells

L Zhao, E Kaser, M Lequio, K D'MELLO… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Lung cancer is the leading cause of mortality due to cancer death.
Treatment of lung adenocarcinoma (LUAD) is still challenging. Cranberries contain many …